A comprehensive view of Sandoz International GmbH. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Sandoz biosimilars Jubbonti and Wyost as interchangeable with Amgen's blockbuster antibody Prolia and Xgeva for osteoporosis and cancer indications; launch timing uncertain due to ongoing patent litigation
Published: March 06, 2024 by MedCityNews.com
Sandoz submits Commitment Letter to Science Based Targets Initiative, pledging to set science-based carbon reduction targets; company to validate its baseline emissions, develop reduction plan over next 24 months
Published: January 31, 2024 by Contify Life Science News
Sandoz begins construction on a US$400.0M biosimilar manufacturing plant in Slovenia expected to be Europe's most efficient biosimilars production site; facility to be fully operational by 2026 and create around 330 new jobs
Published: December 13, 2023 by FiercePharma
Samsung Bioepis settles patent litigation with J&J, paving way for US sales of plaque psoriasis treatment SB17 from February 22, 2025, upon FDA approval; Sandoz to handle commercialization
Published: December 01, 2023 by PharmaShots
Novartis delivers 12% sales and 21% core operating income growth from continuing operations, executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
Published: November 07, 2023 by Contify Life Science News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count